Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Rowe, Steven M ^a   Liu, Bo ^a   Hill, Aubrey ^a   Hathorne, Heather ^a   Cohen, Morty ^b,f   Beamer, John R ^b,g   Accurso, Frank J ^c   Dong, Qunming ^d   Ordoñez, Claudia L ^d,h   Stone, Anne J ^d   Olson, Eric R ^d   Clancy, John P ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f Morty Cohen Research Consulting   (United States)

^g ALK Source Materials Inc   (United States)

^h BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL; ISOPRENALINE; IVACAFTOR; LUMACAFTOR; PLACEBO; SODIUM; UNCLASSIFIED DRUG; VX-809;

ARTICLE; CHLORIDE TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; ION TRANSPORT; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SODIUM TRANSPORT; STANDARDIZATION;

ADULT; AMINO ACID SUBSTITUTION; AMINOPHENOLS; BIOLOGICAL TRANSPORT; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEMOGRAPHY; EPITHELIAL SODIUM CHANNELS; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; MUTATION; NOSE; PLACEBOS; QUINOLONES; SAMPLE SIZE; SODIUM; SOLUTIONS; YOUNG ADULT;

EID: 84880774140     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066955     Document Type: Article

References (32)

1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
2. Rowe SM, Miller S, Sorscher EJ, (2005) Cystic fibrosis. N Engl J Med 352: 1992-2001.
3. Boucher RC, (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58: 157-170.
4. Donaldson SH, Boucher RC, (2007) Sodium channels and cystic fibrosis. Chest 132: 1631-1636.
5. Thelin WR, Boucher RC, (2007) The epithelium as a target for therapy in cystic fibrosis. Curr Opin Pharmacol 7: 290-295.
6. Knowles MR, Paradiso AM, Boucher RC, (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6: 445-455.
7. Leal T, Fajac A, Wallace HL, Lebecque P, Lebacq J, et al. (2008) Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 41: 764-772.
8. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, et al. (2006) Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 174: 787-794.
9. Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, et al. (2002) Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 33: 142-150.
10. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, et al. (2001) Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163: 1683-1692.
11. Hentchel-Franks K, Lozano D, Eubanks-Tarn V, Cobb B, Fan L, et al. (2004) Activation of airway cl- secretion in human subjects by adenosine. Am J Respir Cell Mol Biol 31: 140-146.
12. Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, et al. (2007) Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 132: 1219-1226.
13. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349: 1433-1441.
14. Wilschanski M, Famini H, Strauss-Leviatan N, Rivlin J, Blau H, et al. (2001) Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 17: 1208-1215.
15. Wilschanski M, Famini H, Blau H, Rivlin J, Augarten A, et al. (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161: 860-865.
16. Wilschanski M, (2010) Small molecules to treat cystic fibrosis. Proc Am Thorac Soc 7: 399-403.
17. Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, et al. (2010) An international randomized multicenter comparison of nasal potential difference techniques. Chest 138: 919-928.
18. Segal I, Yaakov Y, Adler SN, Blau H, Broide E, et al. (2008) Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis. J Clin Gastroenterol 42: 810-814.
19. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, et al. (2007) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117: 683-692.
20. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727.
21. Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, et al. (2008) Nasal potential difference in non-classic cystic fibrosis-long term follow up. Pediatr Pulmonol 43: 545-549.
22. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, et al. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003.
23. Rowe SM, Accurso FJ, Clancy JP, (2007) Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 4: 387-398.
24. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, et al. (2007) No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 37: 57-66.
25. LeGrys VA, (2000) Sweat analysis proficiency testing for cystic fibrosis. Pediatr Pulmonol 30: 476-480.
26. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin R, et al. (2011) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax.
27. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, et al. (2006) Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 173: 1139-1144.
28. Sermet-Gaudelus I, Girodon E, Sands D, Stremmler N, Vavrova V, et al. (2010) Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med 182: 929-936.
29. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, et al. (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12-18.
30. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663-1672.
31. Clancy JP, Rowe SR, Young H, (2006) Alternate Analyses of Nasal Potential Difference Measurements to Assess Ion Transport in Human Subjects [abstract]. Pediatr Pulmonol Suppl 41: 301.
32. Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, et al. (2000) Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 1: 105-114.